NASDAQ
9.74USD
-0.96 (-9.01%)
We have scored 15 news catalysts on Absci Corporation (ABSI) over the past 12 months. The biggest single-day move next to one of them came Jun 24, 2026, when ABSI closed +35.9%: “Absci Announces Pricing of $100 Million Underwritten Offering with Leading Strategic and Financial Investors”. Coverage across the window leans positive (average ticker sentiment +0.34). Most of the impact sits in sector healthcare and institutional appeal.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
1.7B
P/E
—
EPS
—
Beta
2.44
52W range
2.24-12.055
Day range
9.47–10.62
Open
10.55
Prev close
10.71
Volume
4.7M
Avg volume
4.6M
Dividend
0.00
IPO
2021-07-22
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Absci Corporation — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for ABSI: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Absci Corporation operates as a biopharmaceutical company primarily focused on discovering novel drug targets and developing new therapeutic compounds. Leveraging its distinctive integrated drug creation platform, the firm generates potential biologic medicines and essential cell lines for manufacturing, which it provides to its collaborators, predominantly within the United States. This advanced platform is instrumental in facilitating the development of biologics by meticulously integrating the traditionally separate stages of drug discovery and cell line engineering into one streamlined process. Absci Corporation was founded in 2011 and is based in Vancouver, Washington.
